Credit Courtesy photo The Arrowhead Innovation Fund has announced an investment in TNeuroPharma, a company creating a new blood test to detect Alzheimer’s disease earlier. Founder and CEO Dr. Kristina Trujillo, a New Mexico State University alumna, said this technology also has the potential to lead to future treatment. TNeuroPharma already has raised over $1.2 million and now AIF will be adding to their growth. Beto Pallares, AIF fund manager, said the early studies by TNeuroPharma have been exciting. “We want to help the commercialization of this product – and the possible treatment – come to market as fast as possible,” Pallares said.